Activation by serotonin and noradrenaline of vasopressin and oxytocin expression in the mouse paraventricular and supraoptic nuclei.
Noradrenaline and serotonin are known to control arginine-vasopressin (AVP) and oxytocin (OT) secretion in the systemic circulation. The aim of the current study was to investigate whether these monoamines are also able to influence AVP and OT expression in the paraventricular (PVN) and supraoptic nuclei (SON). To test this hypothesis, we used the Tg8 transgenic mice KO for the monoamine oxidase-A gene, which present high levels of noradrenaline and serotonin in the brain. AVP and OT expression were evaluated at peptide and mRNA levels by immunohistochemistry, enzyme immunoassay, and in situ hybridization. Compared with wild type, the amounts of AVP, OT, AVP mRNA, and OT mRNA were increased in the PVN and SON in Tg8 mice. To distinguish the respective contributions of noradrenaline and serotonin to these modifications, we treated Tg8 mice with a synthesis inhibitor of either catecholamines [alpha-methylparatyrosine (alpha-MPT)] or serotonin [parachlorophenylalanine (pCPA)]. Administration of alpha-MPT to Tg8 mice induced a decline in the amounts of AVP, OT, and their mRNA in the PVN and SON. The pCPA treatment in Tg8 mice was also associated with a decrease in OT expression in the PVN and SON and in AVP expression in the PVN, but not in the SON. These results suggest that noradrenaline may activate AVP and OT expression in the PVN and SON. Likewise, serotonin is proposed to stimulate AVP and OT expression in the PVN and only OT expression in the SON.
Vacher
Claire-Marie
CM
Laboratory of Neurobiology of Intercellular Signals, Unité Mixte de Recherche 7101, Centre National de la Recherche Scientifique, Pierre and Marie Curie University, 75252 Paris Cedex 05, France. Claire-Marie.Vacher@snv.jussieu.fr
Frétier
Philippe
P
Créminon
Christophe
C
Calas
André
A
Hardin-Pouzet
Hélène
H
D000818:Animals; D001127:Arginine Vasopressin / Q000096:biosynthesis* / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D010134:Fenclonine / Q000494:pharmacology; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D017403:In Situ Hybridization; D051379:Mice; D008809:Mice, Inbred C3H; D008822:Mice, Transgenic; D008995:Monoamine Oxidase / Q000172:deficiency / Q000235:genetics; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology*; D010121:Oxytocin / Q000096:biosynthesis* / Q000235:genetics; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects* / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D013495:Supraoptic Nucleus / Q000187:drug effects* / Q000378:metabolism; D019805:alpha-Methyltyrosine / Q000494:pharmacology
D004791:Enzyme Inhibitors; D012333:RNA, Messenger; D012702:Serotonin Antagonists; D001127:Arginine Vasopressin; D012701:Serotonin; D010121:Oxytocin; D019805:alpha-Methyltyrosine; D008995:Monoamine Oxidase; D010134:Fenclonine; D009638:Norepinephrine